NEW YORK – PerkinElmer announced after the close of the market on Wednesday it has reached a deal to acquire Nexcelom Bioscience for $260 million in cash.
The acquisition is expected to close in the second quarter.
Based in Lawrence, Massachusetts, Nexcelom provides tools and instruments for cell counting and analysis, including automated cell counting instruments, image cytometry workstations, assays, cell reagents and other consumables.
The company also provides fit-for-purpose cell counting method selection and development instruments that follow ISO cell counting standards and aid in developing cell, gene, and immune-oncology therapies; virology drugs; and vaccines. The company was founded in 2003 and has about 130 employees in the US, UK, and China, and it expects 2021 revenues of about $40 million, PerkinElmer said.
Nexcelom's capabilities in drug development, combined with PerkinElmer's drug discovery solutions, "will expand our efforts to help academic, government, and biopharmaceutical organizations streamline their complete workflows and support efforts to accelerate time to target and time to market for novel therapies," PerkinElmer CEO Prahlad Singh said in a statement.